Epigenomics signs agreement with Polymedco

04-Oct-2013 - Germany

Epigenomics AG announced that it has entered into a joint commercialization agreement with Polymedco Inc., a leading provider of colorectal cancer tests in North America. Both companies will jointly commercialize Epi proColon®, Epigenomics' blood-based test for colorectal cancer (CRC) screening, in North America.

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy